Transgene begins dosing in Phase II trial of TG4010 to treat NSCLC
French biotechnology company Transgene has begun dosing patients in a Phase II trial of TG4010 in combination with Bristol-Myers Squibb's Opdivo (nivolumab) to treat metastatic non-small-cell lung cancer (NSCLC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals